Certificate u/r 74(5) for the quarter ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Samrat Pharmachem Ltd has submitted a compliance certificate under SEBI Regulation 74(5) for Q4 FY2026 (ending March 31, 2026). The certificate from Registrar and Transfer Agent MUFG Intime India confirms that securities received for dematerialisation during the quarter were properly processed and confirmed to depositories. The RTA also confirms that security certificates were mutilated and cancelled after verification, and depository names were substituted in the register of members within prescribed timelines. This is a routine regulatory filing required to be submitted within 30 days of quarter end.
This is a standard compliance filing with no direct impact on the company's financials or shareholder value. It confirms proper processing of share dematerialisation requests and does not signal any corporate action.